sar425899 glp-1 glucagon dual agonist sanofi Receptor occupancy of glucagon-like peptide 1/glucagon receptor in individuals with type 2 diabetes Glucagon agonism in the treatment
Description
DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect
A newly published clinical investigation in the British Journal of Anaesthesia (May 2025 issue) reveals compelling evidence linking glucagon-like peptide-1 receptor agonists (GLP-1RAs) to impaired gastric emptying (IGE)
GLP-1s arent for everyone
About half support the use of GLP-1 weight loss drugs for adults with obesity or weight-related conditions, and a similar share the belief that these drugs should be covered by Medicare and Medicaid.
It caused tumors in animal studies
